ABBV-744

• Description:

  ABBV-744 is a first-in-class, orally active and selective inhibitor of the BDII domain of BET family proteins with IC50 values ranging from 4 to 18 nM for BRD2, BRD3, BRD4 and BRDT. ABBV-744 is primarily metabolized by CYP3A4 with agent-like properties enable the investigation of its antitumor efficacy and tolerability[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Epigenetic Reader Domain; HIV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection; Epigenetics

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer; Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/ABBV-744.html

• Purity:

  99.95

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC(O)(C)C1=CC(C(C2=C3NC(C(NCC)=O)=C2)=CN(C)C3=O)=C(OC4=C(C)C=C(F)C=C4C)C=C1

• Molecular Formula:

  C28H30FN3O4

• Molecular Weight:

  491.55

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Faivre EJ, et al. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer. Nature. 2020;578 (7794) :306-310.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, stored under nitrogen)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• Isoform:

  BRD2; BRD3; BRD4; BRDT

• CAS Number:

  [2138861-99-9]